€79.16
Your prediction
Financial data and news for Corcept
sharewise wants to provide you with the best news and tools for Corcept, so we directly link to the best financial data sources.
Financials
News
Corcept Insider Sells Shares After an FDA Approval and a $1.05 Billion Outlook
William Guyer, chief development officer, reported a sale of 20,000 shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) on July 7, 2026, according to an SEC Form 4 filing.
Corcept
Why Corcept Therapeutics Zoomed Nearly 9% Higher This Week
One of the top-performing healthcare stocks mid-week was Corcept Therapeutics (NASDAQ: CORT), and it was little wonder -- the company was granted U.S. Food and Drug Administration (FDA) approval for
Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday
Corcept Therapeutics (NASDAQ: CORT) took its investors for quite a ride on Hump Day. The commercial-stage biotech earned its latest nod from a regulator that afternoon and, not surprisingly, its


